Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
January 2023 in “Pharmaceutics” AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
131 citations,
September 2017 in “Molecular and Cellular Endocrinology” The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.
74 citations,
January 2015 in “Asian Journal of Transfusion Science” Platelet-rich plasma (PRP) injections can effectively increase hair density and thickness in people with androgenic alopecia, without major side effects.
64 citations,
October 2018 in “Thérapie” Enriching the French health care database with external data greatly improved its usefulness.
24 citations,
January 2017 in “International Journal of Trichology” 12 citations,
December 2016 in “PubMed” Hirsutism involves excessive hair growth due to hormonal issues and can be treated with medication or surgery.
10 citations,
February 2021 in “International Journal of Nanomedicine” Chitosan-decorated finasteride nanosystems improve skin retention and could be a better treatment for hair loss.